Tonix Pharmaceuticals Unveils Investor Presentation Highlighting FDA Approvals and Pipeline Advances
I'm PortAI, I can summarize articles.
Tonix Pharmaceuticals Holding Corp. has released an investor presentation detailing its business and clinical activities. The company reported $190 million in cash and no debt, with a cash runway into Q1 2027. It has three FDA-approved products, including TONMYA for fibromyalgia. The presentation also highlights pipeline programs TNX-1500, TNX-2900, and TNX-4800, which are in various clinical stages. The company has deployed 90 sales representatives and established patient access programs.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments